A multicentre, double‐blind, placebo‐controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add‐on therapy in type 2 diabetic patients treated with metformin and dapagliflozin
Diabetes, Obesity and Metabolism · 2024
DOI: 10.1111/dom.15526 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Soo Lim und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seoul, South Korea. Hauptthemen laut MEDLINE: Glucosides, Pioglitazone, Diabetes Mellitus, Type 2, Metformin. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Yooyoung Pharmaceutical Company.
Abstract (Originalsprache)
Aim
To investigate the efficacy and safety of pioglitazone compared to placebo when added to metformin plus dapagliflozin, a sodium‐glucose cotransporter‐2 (SGLT2) inhibitor, for patients with type 2 diabetes mellitus (T2DM). Materials and Methods In a multicentre study, with a randomized, double‐blind, placebo‐controlled design, 249 Korean patients with T2DM suboptimally managed on metformin and dapagliflozin were assigned to receive either pioglitazone (15 mg daily) or placebo for 24 weeks, followed by a 24‐week pioglitazone extension. Primary outcomes included changes in glycated haemoglobin (HbA1c), with secondary outcomes assessing insulin resistance, adiponectin levels, lipid profiles, liver enzymes, body weight and waist circumference.
Results
Pioglitazone administration resulted in a significant reduction in HbA1c levels (from 7.80% ± 0.72% to 7.27% ± 0.82%) compared with placebo (from 7.79% ± 0.76% to 7.69% ± 0.86%, corrected mean difference: −0.42% ± 0.08%; p < 0.01) at 24 weeks. Additional benefits from pioglitazone treatment included enhanced insulin sensitivity, increased adiponectin levels, raised high‐density lipoprotein cholesterol levels and reduced liver enzyme levels, resulting in improvement in nonalcoholic fatty liver disease liver fat score. Despite no serious adverse events in either group, pioglitazone therapy was modestly but significantly associated with weight gain and increased waist circumference.
Conclusions
Adjunctive pioglitazone treatment in T2DM inadequately controlled with metformin and dapagliflozin demonstrates considerable glycaemic improvement, metabolic benefits, and a low risk of hypoglycaemia. These advantages must be weighed against the potential for weight gain and increased waist circumference.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seoul, South Korea.
- Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
- Department of Internal Medicine, Eulji General Hospital, Eulji University School of Medicine, Seoul, South Korea.
- Department of Internal Medicine, Hanyang University Guri Hospital, Guri, South Korea.
- Department of Internal Medicine, Chosun University Hospital, Gwangju, South Korea.
- Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea.
ORCID-Profile: Soo Lim, Seung-Hwan Lee, Nan Hee Kim, Hyuk Sang Kwon, In-Kyung Jeong, Sungrae Kim
Förderung
- Yooyoung Pharmaceutical Company
Zitieren
APA
Lim, S., Lee, S. H., Min, K. W., Lee, C. B., Kim, S. Y., Yoo, H. J., Kim, N. H., Kim, J. H., Oh, S., Won, J. C., Kwon, H. S., Kim, M. K., Park, J. H., Jeong, I. K., & Kim, S. (2024). A multicentre, double‐blind, placebo‐controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add‐on therapy in type 2 diabetic patients treated with metformin and dapagliflozin. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15526
Vancouver
Lim S, Lee SH, Min KW, Lee CB, Kim SY, Yoo HJ, et al. A multicentre, double‐blind, placebo‐controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add‐on therapy in type 2 diabetic patients treated with metformin and dapagliflozin. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15526
BibTeX
@article{Lim2024,
author = {Lim, Soo and Lee, Seung-Hwan and Min, Kyung-Wan and Lee, Chang Beom and Kim, Sang Yong and Yoo, Hye Jin and Kim, Nan Hee and Kim, Jae Hyeon and Oh, Seungjoon and Won, Jong Chul and Kwon, Hyuk Sang and Kim, Mi Kyung and Park, Jung Hwan and Jeong, In-Kyung and Kim, Sungrae},
title = {A multicentre, double‐blind, placebo‐controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add‐on therapy in type 2 diabetic patients treated with metformin and dapagliflozin},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
doi = {10.1111/dom.15526}
}
EUVIMED